title: Fludeoxyglucose F 18 PET-Computed Tomography: Management Changes Effecting Patient Outcomes in Gynecologic Malignancies.
abstract: Outcome analysis in oncologic imaging is complex because of the multiple variables that can affect survival, including how early disease is diagnosed, the accuracy of staging at diagnosis, and where and how the patient is treated. Risk for tumor recurrence is estimated based on tumor histologic grade, stage at diagnosis, and other factors, including expressed molecular markers. This article reviews the data supporting the use of F 18 fluorodeoxyglucose PET-computed tomography in endometrial, ovarian, and cervical malignancies, with emphasis on the impact of imaging on treatment stratification and prognosis.
authors.affiliation: Department of Radiology, Holy Name Medical Center, 718 Teaneck Road, Teaneck, NJ 07666, USA; Department of Radiology, Columbia University Medical Center, 622 W 168th Street, New York, NY 10032, USA. Electronic address: brunetti@mail.holyname.org.
authors.forename: Jacqueline C
authors.initials: JC
authors.lastname: Brunetti
mesh_terms: D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D064847:Multimodal Imaging / Q000379:methods*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed / Q000379:methods*; D014594:Uterine Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: (18)F FDG PET; Cervical cancer; Endometrial cancer; Ovarian cancer; PET-CT